Cargando…

An Inflammatory Story: Antibodies in Tuberculosis Comorbidities

Mycobacterium tuberculosis (Mtb) resides in a quarter of the world's population and is the causative agent for tuberculosis (TB), the most common infectious reason of death in humans today. Although cellular immunity has been firmly established in the control of Mtb, there is growing evidence t...

Descripción completa

Detalles Bibliográficos
Autores principales: McLean, Milla R., Lu, Lenette L., Kent, Stephen J., Chung, Amy W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6913197/
https://www.ncbi.nlm.nih.gov/pubmed/31921122
http://dx.doi.org/10.3389/fimmu.2019.02846
_version_ 1783479617453031424
author McLean, Milla R.
Lu, Lenette L.
Kent, Stephen J.
Chung, Amy W.
author_facet McLean, Milla R.
Lu, Lenette L.
Kent, Stephen J.
Chung, Amy W.
author_sort McLean, Milla R.
collection PubMed
description Mycobacterium tuberculosis (Mtb) resides in a quarter of the world's population and is the causative agent for tuberculosis (TB), the most common infectious reason of death in humans today. Although cellular immunity has been firmly established in the control of Mtb, there is growing evidence that antibodies may also modulate the infection. More specifically, certain antibody features are associated with inflammation and are divergent in different states of human infection and disease. Importantly, TB impacts not just the healthy but also those with chronic conditions. While HIV represents the quintessential comorbid condition for TB, recent epidemiological evidence shows that additional chronic conditions such as diabetes and kidney disease are rising. In fact, the prevalence of diabetes as a comorbid TB condition is now higher than that of HIV. These chronic diseases are themselves independently associated with pro-inflammatory immune states that encompass antibody profiles. This review discusses isotypes, subclasses, post-translational modifications and Fc-mediated functions of antibodies in TB infection and in the comorbid chronic conditions of HIV, diabetes, and kidney diseases. We propose that inflammatory antibody profiles, which are a marker of active TB, may be an important biomarker for detection of TB disease progression within comorbid individuals. We highlight the need for future studies to determine which inflammatory antibody profiles are the consequences of comorbidities and which may potentially contribute to TB reactivation.
format Online
Article
Text
id pubmed-6913197
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-69131972020-01-09 An Inflammatory Story: Antibodies in Tuberculosis Comorbidities McLean, Milla R. Lu, Lenette L. Kent, Stephen J. Chung, Amy W. Front Immunol Immunology Mycobacterium tuberculosis (Mtb) resides in a quarter of the world's population and is the causative agent for tuberculosis (TB), the most common infectious reason of death in humans today. Although cellular immunity has been firmly established in the control of Mtb, there is growing evidence that antibodies may also modulate the infection. More specifically, certain antibody features are associated with inflammation and are divergent in different states of human infection and disease. Importantly, TB impacts not just the healthy but also those with chronic conditions. While HIV represents the quintessential comorbid condition for TB, recent epidemiological evidence shows that additional chronic conditions such as diabetes and kidney disease are rising. In fact, the prevalence of diabetes as a comorbid TB condition is now higher than that of HIV. These chronic diseases are themselves independently associated with pro-inflammatory immune states that encompass antibody profiles. This review discusses isotypes, subclasses, post-translational modifications and Fc-mediated functions of antibodies in TB infection and in the comorbid chronic conditions of HIV, diabetes, and kidney diseases. We propose that inflammatory antibody profiles, which are a marker of active TB, may be an important biomarker for detection of TB disease progression within comorbid individuals. We highlight the need for future studies to determine which inflammatory antibody profiles are the consequences of comorbidities and which may potentially contribute to TB reactivation. Frontiers Media S.A. 2019-12-09 /pmc/articles/PMC6913197/ /pubmed/31921122 http://dx.doi.org/10.3389/fimmu.2019.02846 Text en Copyright © 2019 McLean, Lu, Kent and Chung. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
McLean, Milla R.
Lu, Lenette L.
Kent, Stephen J.
Chung, Amy W.
An Inflammatory Story: Antibodies in Tuberculosis Comorbidities
title An Inflammatory Story: Antibodies in Tuberculosis Comorbidities
title_full An Inflammatory Story: Antibodies in Tuberculosis Comorbidities
title_fullStr An Inflammatory Story: Antibodies in Tuberculosis Comorbidities
title_full_unstemmed An Inflammatory Story: Antibodies in Tuberculosis Comorbidities
title_short An Inflammatory Story: Antibodies in Tuberculosis Comorbidities
title_sort inflammatory story: antibodies in tuberculosis comorbidities
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6913197/
https://www.ncbi.nlm.nih.gov/pubmed/31921122
http://dx.doi.org/10.3389/fimmu.2019.02846
work_keys_str_mv AT mcleanmillar aninflammatorystoryantibodiesintuberculosiscomorbidities
AT lulenettel aninflammatorystoryantibodiesintuberculosiscomorbidities
AT kentstephenj aninflammatorystoryantibodiesintuberculosiscomorbidities
AT chungamyw aninflammatorystoryantibodiesintuberculosiscomorbidities
AT mcleanmillar inflammatorystoryantibodiesintuberculosiscomorbidities
AT lulenettel inflammatorystoryantibodiesintuberculosiscomorbidities
AT kentstephenj inflammatorystoryantibodiesintuberculosiscomorbidities
AT chungamyw inflammatorystoryantibodiesintuberculosiscomorbidities